Faes Farma, S.A.
FAE.MC

$1.23 B
Marketcap
$3.96
Share price
Country
$0.05
Change (1 day)
$4.14
Year High
$3.10
Year Low

Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.

marketcap

P/E ratio for Faes Farma, S.A. (FAE.MC)

P/E ratio as of 2023: 10.66

According to Faes Farma, S.A.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 10.66. At the end of 2022 the company had a P/E ratio of 11.99.

P/E ratio history for Faes Farma, S.A. from 2003 to 2023

PE ratio at the end of each year

Year P/E ratio
2023 10.66
2022 11.99
2021 12.31
2020 13.46
2019 21.36
2018 15.31
2017 18.09
2016 23.10
2015 22.88
2014 16.31
2013 26.18
2012 17.36
2011 17.59
2010 25.73
2009 32.94
2008 18.68
2007 44.95
2006 88.59
2005 48.44
2004 72.73
2003 83.51